Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: The GenHAT study

Pharmacogenetics and Genomics

Volumn 18, Issue 8, 2008, Pages 651-656

  Maitland Van Der Zee, Anke Hilse ^a,e   Lynch, Amy ^b   Boerwinkle, Eric ^c   Arnett, Donna K ^d   Davis, Barry R ^c   Leiendecker Foster, Catherine ^b   Ford, Charles E ^c   Eckfeldt, John H ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cystathionine beta synthetase gene (CBSins); Homocysteine; Methylenetetrahydrofolate reductase gene; Pharmacogenetics; Statin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHLORTALIDONE; CYSTATHIONINE BETA SYNTHASE; DOXAZOSIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PRAVASTATIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; RANDOMIZED CONTROLLED TRIAL;

AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; KAPLAN-MEIERS ESTIMATE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 55749089900     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282fe1759     Document Type: Article

References (26)

1. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatine Survival Study. Lancet 1994; 344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, et al. Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
3. Sacks F, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatine on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
4. Anonymous. Prevention of cardiovascular events and death with pravastatine in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatine in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279:1615-1622.
6. Anonymous. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high risk individuals; a randomized placebo controlled trial. Lancet 2002; 360:7-22.
7. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 287:3215-3222.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc 2002; 288:2998-3007.
9. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336:153-162.
10. Maitland-van der Zee AH, Klungel OH, Stricker BCh, Verschuren W, Kastelein JJP, Leufkens HGM, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163:213-222.
11. Doevendans PA, Jukema JW, Spiering W, Defesche JC, Kastelein JJP. Molecular genetics and gene expression in atherosclerosis. Int J Cardiol 2001; 80:161-172.
12. Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Weiss G, Fuchs D. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clin Chem Lab Med 2005; 43:1373-1376.
13. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999; 29:8-19; discussion 19-21.
14. Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis 2005; 181:159-165.
15. Surdacki A, Stochmal E, Szurkowska M, Bode-Boger SM, Martens-Lobenhoffer J, Stochmal A, et al. Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance. Metabolism 2007; 56:77-86.
16. Urreizti R, Asteggiano C, Vilaseca MA, Corbella E, Pinto X, Grinberg D, et al. A CBS haplotype and a polymorphism at the MSR gene are associated with cardiovascular disease in a Spanish case-control study. Clin Biochem 2007; 40:864-868.
17. Guerzoni AR, Pavarino-Bertelli EC, Godoy MF, Graca CR, Biselli PM, Souza DR, et al. Methylenetetrahydrofolate reductase gene polymorphism and its association with coronary artery disease. Sao Paulo Med J 2007; 125:4-8.
18. Jankowski P, Kawecka-Jaszcz K. Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs. Atherosclerosis 2004; 172:191-194.
19. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9 (4 Pt 1):342-360.
20. Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, et al. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials 2001; 22:674-686.
21. Wright JT Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Control Clin Trials 2001; 22:659-673.
22. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999; 9:936-949.
23. Garcia-Pinilla JM, Espinosa-Caliani S, Jimenez-Navarro M, Gomez-Doblas JJ, Cabrera-Bueno F, Teresa-Galvan E. Influence of 677 C-T poymorphism on medium term prognosis after acute coronary syndrome. Tex Heart Inst J 2007; 34:142-147.
24. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-1588.
25. Toole JFT, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. J Am Med Assoc 2004; 291:565-575.
26. Anonymous. Homocysteine lowering with folic acid and B vitamins in vascular disease. The Heart Outcomes Prevention Evaluation (HOPE) 2 investigators. N Engl J Med 2006; 354:1567-1577.